RSS   Newsletter   Contact   Advertise with us
Post Online Media

NantKwest appoints Fred Driscoll to board

NantKwestNantKwest, a clinical-stage immunotherapy company, announced that Fred Driscoll has been appointed to the board.
Article continues below

READ MORE Getty Realty Corp. appoints David B. Driscoll as new president and CEO

Joining NantKwest’s Board, Mr. Driscoll brings more than 30 years of deep financial and commercialization experience in the biotechnology and medical device industries.

Prior to joining NantKwest, Mr. Driscoll has been an Advisor of Flexion Therapeutics, Inc. and served as the Chief Financial Officer of Flexion Therapeutics, Inc. from 2013 until his retirement earlier this year.

Prior to Flexion, he served as the Chief Financial Officer, Vice President, Treasurer and Principal Accounting Officer of Novavax, Inc.

He served as the Chief Executive Officer and President at Genelabs Technologies, Inc. and also served as its Chief Financial Officer.

Earlier in his career, Mr. Driscoll was Chief Financial Officer of Astraris, Inc., Chief Executive Officer and President of OXiGENE, Inc., and Senior Vice President of Finance and Operations of Collagenesis Corporation.

He has more than 30 years of financial management experience with biotechnology and medical device companies.

Mr. Driscoll has a Bachelor’s degree in Accounting and Finance from Bentley University in Waltham, Massachusetts.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy